Ways and Means Committee
- Referred To
Introduced: Feb 18, 2025
Latest action date: Feb 18, 2025
Latest development
Referred to the House Committee on Ways and Means.
Civixly approval
No ratings yet
Not enough ratings yet. Public approval appears at 5+ ratings.
Status detail: The most advanced recorded stage is committee consideration.
Plain-language overview
Cameron's Law
This bill increases the orphan drug tax credit to 50% (from 25%) of qualified clinical testing expenses paid or incurred in the development of drugs to treat certain rare diseases or conditions.
As background, the Tax Cuts and Jobs Act reduced the orphan drug tax credit (for tax years after 2017) to 25% of qualified clinical testing expenses (e.g., wages, supplies, and certain contract expenses) paid or incurred in the development of drugs to treat certain rare diseases or conditions. For 2017 and prior tax years, the orphan tax credit was 50% of such expenses paid or incurred.
Official summary from Congress.gov.
Civixly topics
Civixly topics make federal and state legislation comparable. They are derived from the official CRS policy area and legislative subjects.
Official CRS policy area
Taxation
Committees and subcommittees that received, reviewed, marked up, or reported this legislation.
Proposed changes to this measure, with their latest official outcome or action from Congress.gov.
No amendments are listed for this measure.
Checked against Congress.gov Oct 21, 2026.
Newest action first. Action language comes from the official Congress.gov record.
Referred to the House Committee on Ways and Means.
Introduced in House
Introduced in House
Recorded House and Senate votes connected to this bill. Your representatives appear first when available.
No connected roll-call votes are currently available for this bill.
0 comments across 0 threads
Loading comments...